000061971 001__ 61971
000061971 005__ 20210526094556.0
000061971 0247_ $$2doi$$a10.1038/ncomms16085
000061971 0248_ $$2sideral$$a100829
000061971 037__ $$aART-2017-100829
000061971 041__ $$aeng
000061971 100__ $$0(orcid)0000-0001-7897-9173$$aAguilo, Nacho$$uUniversidad de Zaragoza
000061971 245__ $$aReactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis
000061971 260__ $$c2017
000061971 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061971 5203_ $$aMTBVAC is a live-attenuated Mycobacterium tuberculosis vaccine, currently under clinical development, that contains the major antigens ESAT6 and CFP10. These antigens are absent from the current tuberculosis vaccine, BCG. Here we compare the protection induced by BCG and MTBVAC in several mouse strains that naturally express different MHC haplotypes differentially recognizing ESAT6 and CFP10. MTBVAC induces improved protection in C3H mice, the only of the three tested strains reactive to both ESAT6 and CFP10. Deletion of both antigens in MTBVAC reduces its efficacy to BCG levels, supporting a link between greater efficacy and CFP10- and ESAT6-specific reactogenicity. In addition, MTBVAC (but not BCG) triggers a specific response in human vaccinees against ESAT6 and CFP10. Our results warrant further exploration of this response as potential biomarker of protection in MTBVAC clinical trials.
000061971 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
000061971 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000061971 590__ $$a12.353$$b2017
000061971 591__ $$aMULTIDISCIPLINARY SCIENCES$$b3 / 64 = 0.047$$c2017$$dQ1$$eT1
000061971 592__ $$a6.582$$b2017
000061971 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2017$$dQ1
000061971 593__ $$aPhysics and Astronomy (miscellaneous)$$c2017$$dQ1
000061971 593__ $$aChemistry (miscellaneous)$$c2017$$dQ1
000061971 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061971 700__ $$0(orcid)0000-0001-8841-6593$$aGonzalo-Asensio, Jesús$$uUniversidad de Zaragoza
000061971 700__ $$0(orcid)0000-0002-5748-6078$$aAlvarez-Arguedas, Samuel$$uUniversidad de Zaragoza
000061971 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, Dessislava$$uUniversidad de Zaragoza
000061971 700__ $$0(orcid)0000-0002-9713-2127$$aGomez, Ana Belen$$uUniversidad de Zaragoza
000061971 700__ $$0(orcid)0000-0001-7866-2803$$aUranga, Santiago$$uUniversidad de Zaragoza
000061971 700__ $$aSpallek, Ralf
000061971 700__ $$aSingh, Mahavir
000061971 700__ $$aAudran, Regine
000061971 700__ $$aSpertini, François
000061971 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000061971 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000061971 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000061971 773__ $$g8 (2017), 16085 [11 pp.]$$pNATURE COMMUNICATIONS$$tNature Communications$$x2041-1723
000061971 8564_ $$s1038065$$uhttps://zaguan.unizar.es/record/61971/files/texto_completo.pdf$$yVersión publicada
000061971 8564_ $$s67492$$uhttps://zaguan.unizar.es/record/61971/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061971 909CO $$ooai:zaguan.unizar.es:61971$$particulos$$pdriver
000061971 951__ $$a2021-05-26-09:31:16
000061971 980__ $$aARTICLE